Government
COVID-19 is a respiratory illness and presents many other symptoms, including blood clots. For more details and other COVID-19 news, continue reading.
This particular renewal panel discussion took an unexpected turn, focusing on Biogen’s controversial drug.
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
Recent FDA approval of ViiV Healthcare’s HIV treatment Cabenuva reduced dosing to once every two months.
According to a statement from China’s NHSA, AstraZeneca staff members are suspected of tampering with the genetic testing results of cancer patients in order to defraud medical insurance funds.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Americans pay the highest drug prices in the world while importing drugs for lower prices from other countries has been locked down on a personal level and labeled as “unsafe.”
The U.S. Supreme Court blocked the mandate earlier this month, stating that OSHA had overstepped its authority.
As Omicron continues to dominate globally, research is coming in every day on this highly contagious variant of SARS-CoV-2.
PRESS RELEASES